Rhythm Pharmaceuticals (RYTM) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
3 Nov, 2026Executive summary
Q3 global IMCIVREE net product revenue was $92.1M, up 29% QoQ and 80% YoY; reimbursed patients on therapy grew 20% globally.
U.S. acquired HO launch momentum continued, with more than 700 patient start forms from over 500 prescribers by Sept. 30; Japan commercialization began in October.
Bivamelagon is advancing toward Phase 3 trials for acquired HO and PWS; a revised LG Chem license and term-loan facility added financing capacity and future obligations.
Financial highlights
Q3 net product revenue was $92.1M versus $51.3M in Q3 2025 and $71.3M in Q2 2026.
Q3 U.S. product revenue was $67.5M; international revenue was $24.7M. U.S. revenue represented 73% of product revenue.
Q3 R&D expense was $52.5M and SG&A was $66.8M; operating expenses were $119.2M, including $25.0M in stock-based compensation.
GAAP diluted loss per share was $0.61 versus $0.82 in Q3 2025; cash, cash equivalents and short-term investments totaled $320.9M at Sept. 30.
Outlook and guidance
2026 non-GAAP operating expense guidance is $360M–$380M: R&D $165M–$175M and SG&A $195M–$205M; guidance excludes stock-based compensation and fixed in-license and milestone consideration.
Cash at Sept. 30 is expected to fund planned operations for at least 24 months; that balance excludes the initial term-loan draw and the $70M LG Chem payment due.
A 52-week global placebo-controlled Phase 3 bivamelagon acquired-HO trial is planned, with BMI reduction as its primary endpoint; first sites are expected to screen by year-end 2026.
A six-month Phase 3 bivamelagon PWS study is planned for 2027, pending regulator alignment; acquired-HO launches in additional European countries are expected from 2027, beginning with Germany.
Latest events from Rhythm Pharmaceuticals
- AHO launch expands as 2027 plans target ex-U.S. growth and bivamelagon trials.RYTM
Stifel 2026 Healthcare Conference 2026 - Steady HO launch progress and expanding MC4R trials support a growing opportunity.RYTM
3rd Annual Guggenheim Healthcare Innovation Conference - Early HO launch shows strong physician interest and payer adoption, with global expansion planned.RYTM
Morgan Stanley 24th Annual Global Healthcare Conference - HO launch gains traction, Prader-Willi trials advance, and financials support robust investment.RYTM
Wells Fargo 21st Annual Healthcare Conference - IMCIVREE drives global growth as MC4R therapies expand for rare obesity syndromes.RYTM
Corporate presentation - Strong AHO launch, global expansion, and advancing pipeline position the company for growth.RYTM
Canaccord Genuity's 46th Annual Growth Conference - Q2 2026 revenue climbed 47% to $71.3M, led by IMCIVREE's U.S. launch and global expansion.RYTM
Q2 2026 - Q3 2025 revenue up 54% to $51.3M, net loss $54.3M, $416.1M cash, key milestones ahead.RYTM
Q3 2025 - IMCIVREE sales and pivotal trial success drive revenue growth and improved financial outlook.RYTM
Q1 2025